Full TitlePevonedistat as a Single Agent and in Combination with Chemotherapy in Patients with Malignant Mesothelioma
The purpose of this study is to assess the safety and effectiveness of the investigational drug pevonedistat in patients with inoperable pleural or peritoneal malignant mesothelioma. Pevonedistat works against cancer by inhibiting an enzyme that mesothelioma cells use to grow.
Patients who previously had treatment for their mesothelioma will receive pevonedistat alone, and those who have not received prior treatment will receive pevonedistat in plus standard chemotherapy (pemetrexed and cisplatin). Pevonedistat and the chemotherapy drugs used in this study are given intravenously (by vein).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have inoperable mesothelioma of the pleura or peritoneum.
- Patients who had prior therapy must have received pemetrexed and a platinum-based drug. At least 3 weeks must pass between the completion of previous treatment and entry into the study.
- This study is for patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Marjorie Zauderer at 646-888-4656.